AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36471413 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 171
Study 36471413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 35342036 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 84
Study 33227280 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Immunochemical Test (FIT) screening every second year
Number of subjects: 139291
Study 33227280 — intervention group
Group type: COMPARATOR
Intervention: Sigmoidoscopy
Number of subjects: 139291
Study 33227280 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Immunochemical Test (FIT) screening
Number of subjects: 139291
Study 33549489 — intervention group
Group type: EXPERIMENTAL
Intervention: APC Plus adhesive coated appliance system with moisture insensitive primer (MIP) under wet conditions
Number of subjects: 24
Study 33549489 — intervention group
Group type: EXPERIMENTAL
Intervention: APC Plus adhesive coated appliance system with moisture insensitive primer (MIP) under dry conditions
Number of subjects: 24
Study 33549489 — intervention group
Group type: COMPARATOR
Intervention: APC Plus adhesive coated appliance system with moisture insensitive primer (MIP) under wet and dry conditions
Number of subjects: 24
Study 33068631 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS
Number of subjects: 22
Study 33068631 — intervention group
Group type: COMPARATOR
Intervention: SHAM TMS
Number of subjects: 22
Study 35343999 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (brochure and questionnaire on attitudes toward deprescribing)
Number of subjects: 3012
Study 35343999 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 3012
Study 33587893 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete mesocolic excision (CME)
Number of subjects: 995
Study 33587893 — intervention group
Group type: COMPARATOR
Intervention: D2 dissection
Number of subjects: 995
Study 36177365 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybuprocaine hydrochloride gel as urethral lubricant
Number of subjects: 192
Study 36177365 — intervention group
Group type: COMPARATOR
Intervention: Liquid paraffin
Number of subjects: 192
Study 35998039 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (1,000 mg) and pterostilbene (200 mg) supplementation
Number of subjects: 32
Study 35998039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 32347815 — intervention group
Group type: EXPERIMENTAL
Intervention: MILK intervention (n=126)
Number of subjects: 250
Study 32347815 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving general perinatal SMS text messaging (Text4Baby; n=124)
Number of subjects: 250
Study 35222888 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological care plus Chinese herbal decoction treatment
Number of subjects: 80
Study 35222888 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy
Number of subjects: 80
Study 33683334 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassion Cultivation Training (CCT)
Number of subjects: 161
Study 33683334 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 161
Study 32988938 — intervention group
Group type: EXPERIMENTAL
Intervention: Public Health (PH) advertisements
Number of subjects: 2923
Study 32988938 — intervention group
Group type: COMPARATOR
Intervention: SAPRO advertisements
Number of subjects: 2923
Study 33103316 — intervention group
Group type: EXPERIMENTAL
Intervention: ADSC-CM plus 2% niacinamide
Number of subjects: 25
Study 33103316 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 25
Study 32532258 — intervention group
Group type: EXPERIMENTAL
Intervention: Danirixin 5, 10, 25, 35 or 50 mg twice daily
Number of subjects: 614
Study 32532258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study 34004123 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Pulmonary Rehabilitation (EPR)
Number of subjects: 207
Study 34004123 — intervention group
Group type: COMPARATOR
Intervention: Traditional Pulmonary Rehabilitation (PR)
Number of subjects: 207
Study 32865377 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg once daily)
Number of subjects: 3730
Study 32865377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3730
Study 36273218 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU weekly for 8 weeks)
Number of subjects: 50
Study 36273218 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1000 mg olive oil weekly for 8 weeks)
Number of subjects: 50
Study 32791888 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention at Norwegian Healthy Life Centres
Number of subjects: 118
Study 32791888 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 118
Study 35619238 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized diaphragmatic stimulation (SDS)
Number of subjects: 15
Study 32563179 — intervention group
Group type: EXPERIMENTAL
Intervention: iPlayClean anti-doping education programme (face-to-face group presentation)
Number of subjects: 1081
Study 32563179 — intervention group
Group type: EXPERIMENTAL
Intervention: iPlayClean anti-doping education programme (online)
Number of subjects: 1081
Study 32563179 — intervention group
Group type: EXPERIMENTAL
Intervention: iPlayClean anti-doping education programme (face-to-face presentation with online access)
Number of subjects: 1081
Study 32563179 — intervention group
Group type: EXPERIMENTAL
Intervention: iPlayClean anti-doping education programme (all modes)
Number of subjects: 1081
Study 32563179 — intervention group
Group type: EXPERIMENTAL
Intervention: iPlayClean anti-doping education programme (face-to-face presentation)
Number of subjects: 1081
Study 32563179 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1081
Study 35565880 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of whey protein (WP30)
Number of subjects: 8
Study 35565880 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 g of whey protein (WP70)
Number of subjects: 8
Study 35565880 — intervention group
Group type: COMPARATOR
Intervention: Non-caloric control (2 kcal)
Number of subjects: 8
Study 34593169 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mail campaign using behavioral economics insights
Number of subjects: 12000
Study 34593169 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages used in the intervention
Number of subjects: 12000
Study 35470320 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial ultrasound (TCS) with insonation angle >35 degrees
Number of subjects: 100000
Study 35470320 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial ultrasound (TCS) with insonation angle ≤15 degrees
Number of subjects: 100000
Study 32910352 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologically empowered with safer sex intentions (profile 1)
Number of subjects: 275
Study 32910352 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologically disempowered with safer sex intentions (profile 2)
Number of subjects: 275
Study 32910352 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologically disempowered without safer sex intentions (profile 3)
Number of subjects: 275
Study 34980223 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL200+MTX
Number of subjects: 0
Study 34980223 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL100+MTX
Number of subjects: 0
Study 34980223 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL200
Number of subjects: 0
Study 34980223 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 0
Study 34980223 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA
Number of subjects: 0
Study 34980223 — intervention group
Group type: COMPARATOR
Intervention: PBO+MTX
Number of subjects: 0
Study 34980223 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL200+csDMARD
Number of subjects: 0
Study 34980223 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL100+csDMARD
Number of subjects: 0
Study 34980223 — intervention group
Group type: COMPARATOR
Intervention: PBO+csDMARD
Number of subjects: 0
Study 34980223 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL200+MTX, FIL100+MTX, FIL200, FIL100, ADA
Number of subjects: 0
Study 34762377 — intervention group
Group type: EXPERIMENTAL
Intervention: ZHU Lian inhibition type Ⅰ acupuncture
Number of subjects: 82
Study 34762377 — intervention group
Group type: COMPARATOR
Intervention: danshentong capsules (1 g, 3 times per day) and 0.1% adapalene gel smear (once every night) for 4 weeks
Number of subjects: 82
Study 34196450 — intervention group
Group type: EXPERIMENTAL
Intervention: PBS programmes
Number of subjects: 240
Study 34196450 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240
Study 32544970 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate in combination with prednisone/prednisolone (abiraterone/P)
Number of subjects: 0
Study 32544970 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0
Study 32544970 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study 34854095 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg b.d.
Number of subjects: 944
Study 34854095 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg b.d.
Number of subjects: 944
Study 34854095 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (both dosages combined)
Number of subjects: 944
Study 32000070 — intervention group
Group type: EXPERIMENTAL
Intervention: QL block (0.375% ropivacaine 20 ml bilaterally)
Number of subjects: 80
Study 32000070 — intervention group
Group type: COMPARATOR
Intervention: TAP block (0.375% ropivacaine 20 ml bilaterally)
Number of subjects: 80
Study 35549730 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 103247
Study 35549730 — intervention group
Group type: COMPARATOR
Intervention: Non-SGLT2 inhibitors
Number of subjects: 103247
Study 32220129 — intervention group
Group type: COMPARATOR
Intervention: BVM-only
Number of subjects: 3004
Study 32220129 — intervention group
Group type: COMPARATOR
Intervention: BVM-rescue
Number of subjects: 3004
Study 34998391 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 150 mg (new coated tablet)
Number of subjects: 111
Study 34998391 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine 15 mg (new formulation)
Number of subjects: 111
Study 34998391 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine 5 mg (new formulation)
Number of subjects: 111
Study 32162278 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliance therapy (OAT) with a standardized stepwise titration protocol, starting at 60% of the maximum mandibular protrusion position.
Number of subjects: 36
Study 36103970 — intervention group
Group type: EXPERIMENTAL
Intervention: 20° angle in reverse Trendelenburg (RT) position
Number of subjects: 91
Study 36103970 — intervention group
Group type: COMPARATOR
Intervention: 0° supine position
Number of subjects: 91
Study 32205221 — intervention group
Group type: EXPERIMENTAL
Intervention: RPC4046 (360 mg/wk)
Number of subjects: 66
Study 32205221 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by RPC4046 (360 mg/wk)
Number of subjects: 66
Study 35238873 — intervention group
Group type: EXPERIMENTAL
Intervention: HD201
Number of subjects: 502
Study 35238873 — intervention group
Group type: COMPARATOR
Intervention: Referent trastuzumab
Number of subjects: 502
Study 33837566 — intervention group
Group type: EXPERIMENTAL
Intervention: Family planning services (FPs) and sexual and reproductive health (SRH)
Number of subjects: 17555
Study 33837566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine devices (IUD)
Number of subjects: 17555
Study 33837566 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubal ligation
Number of subjects: 17555
Study 33837566 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasectomy
Number of subjects: 17555
Study 33837566 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive failure
Number of subjects: 17555
Study 33837566 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective contraceptive usage after failure (TL and vasectomy)
Number of subjects: 17555
Study 33837566 — intervention group
Group type: EXPERIMENTAL
Intervention: Naïve contraceptive users
Number of subjects: 17555
Study 33837566 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors, awareness on FPs/SRH, discussing and making joint decision, and gender discrepancies
Number of subjects: 17555
Study 36064594 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise group (MIAEG), 30-40 min/session, 3 days/week for 12 weeks
Number of subjects: 60
Study 36064594 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise group (MIAEG)
Number of subjects: 60
Study 36064594 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG), no changes in exercise habits
Number of subjects: 60
Study 34351020 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 34351020 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course glucocorticoids (GC)
Number of subjects: 0
Study 34351020 — intervention group
Group type: EXPERIMENTAL
Intervention: FcRn blockers (SYNT001)
Number of subjects: 0
Study 34351020 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib (PRN1008)
Number of subjects: 0
Study 34764037 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to ImmsLink software and training for pharmacists
Number of subjects: 501
Study 32493407 — intervention group
Group type: COMPARATOR
Intervention: Immediate orally administered amoxicillin (clarithromycin)
Number of subjects: 399
Study 32493407 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ciprofloxacin 0.3% eardrops
Number of subjects: 399
Study 32493407 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed orally administered amoxicillin (clarithromycin if penicillin allergic)
Number of subjects: 399
Study 35128820 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g/day SQ-LNS
Number of subjects: 735
Study 35128820 — intervention group
Group type: COMPARATOR
Intervention: Control (no dietary supplementation)
Number of subjects: 735
Study 34347254 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg capecitabine (test formulation)
Number of subjects: 48
Study 34347254 — intervention group
Group type: COMPARATOR
Intervention: Branded reference formulation
Number of subjects: 48
Study 36205814 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Circuit Training (MCT)
Number of subjects: 7
Study 36205814 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 7
Study 33651758 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 10
Study 33651758 — intervention group
Group type: EXPERIMENTAL
Intervention: Just-in-time CPR training
Number of subjects: 10
Study 33651758 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 10
Study 36809520 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirituality-based palliative care (four 120-min sessions)
Number of subjects: 80
Study 36809520 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study 32642953 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental extraction + PBMT (n = 19)
Number of subjects: 40
Study 32642953 — intervention group
Group type: COMPARATOR
Intervention: Dental extraction + sham-PBMT (n = 21)
Number of subjects: 40
Study 34254318 — intervention group
Group type: COMPARATOR
Intervention: Anti-racist recommendations proposed by Professors N. Patel, R. Smith, or no one (control)
Number of subjects: 395
Study 34254318 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-racist recommendations
Number of subjects: 395
Study 34254318 — intervention group
Group type: COMPARATOR
Intervention: White students
Number of subjects: 395
Study 34666734 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression
Number of subjects: 184
Study 34666734 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic arthroscopy
Number of subjects: 184
Study 34666734 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 184
Study 34666734 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 184
Study 32881921 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive active mobilization with dose and training load control
Number of subjects: 118
Study 32881921 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 118
Study 36153475 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 32244170 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine-augmentation during exposure therapy
Number of subjects: 60
Study 32244170 — intervention group
Group type: COMPARATOR
Intervention: Placebo during exposure therapy
Number of subjects: 60
Study 35785595 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Number of subjects: 512
Study 35785595 — intervention group
Group type: COMPARATOR
Intervention: Investigator-chosen chemotherapy (ICC)
Number of subjects: 512
Study 32600189 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured patient education intervention
Number of subjects: 80
Study 32600189 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured patient education)
Number of subjects: 80
Study 32278848 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-pocket cost information provided by LCS centers
Number of subjects: 55
Study 32278848 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessibility of cost information via telephone or website
Number of subjects: 55
Study 32278848 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility and state-level characteristics
Number of subjects: 55
Study 35746522 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose BNT162b2 (15 µg)
Number of subjects: 100
Study 35746522 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose BNT162b2 (30 µg)
Number of subjects: 100
Study 33755149 — intervention group
Group type: EXPERIMENTAL
Intervention: WDTE60N (150 mg curcuminoids)
Number of subjects: 14
Study 33755149 — intervention group
Group type: COMPARATOR
Intervention: STE95 (500 mg curcuminoids each)
Number of subjects: 14
Study 35634544 — intervention group
Group type: EXPERIMENTAL
Intervention: Madhav Rasayan Plus tablets (250 mg) twice a day for 15 days, along with standard care (SOC)
Number of subjects: 40
Study 35634544 — intervention group
Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 40
Study 33413452 — intervention group
Group type: EXPERIMENTAL
Intervention: HK Chinese SF‐12v2
Number of subjects: 1013
Study 33413452 — intervention group
Group type: COMPARATOR
Intervention: English SF‐12v2
Number of subjects: 1013
Study 36269582 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic double-bundle (DB) technique
Number of subjects: 105
Study 36269582 — intervention group
Group type: COMPARATOR
Intervention: Anatomic single-bundle (SB) technique
Number of subjects: 105
Study 34670502 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Activity Program (TAP)
Number of subjects: 250
Study 34670502 — intervention group
Group type: COMPARATOR
Intervention: Attention Control
Number of subjects: 250
Study 32334146 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational video
Number of subjects: 455
Study 32334146 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative video
Number of subjects: 455
Study 35325125 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 29
Study 35325125 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 29
Study 34779293 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates Exercises (PE)
Number of subjects: 52
Study 34779293 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercises (AE)
Number of subjects: 52
Study 34733674 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A palmitate (VAP) eye gel
Number of subjects: 240
Study 34733674 — intervention group
Group type: EXPERIMENTAL
Intervention: Watson's theory of care nursing + VAP eye gel
Number of subjects: 240
Study 34733674 — intervention group
Group type: EXPERIMENTAL
Intervention: Watson's theory of care nursing
Number of subjects: 240
Study 34733674 — intervention group
Group type: COMPARATOR
Intervention: Control group (no VAP eye gel)
Number of subjects: 240
Study 35930850 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR) training
Number of subjects: 277
Study 35930850 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group (CG)
Number of subjects: 277
Study 33327452 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-facilitated problem-solving based self-learning program (PBSP) in addition to usual care
Number of subjects: 114
Study 33327452 — intervention group
Group type: COMPARATOR
Intervention: Family psychoeducation group program and usual psychiatric care
Number of subjects: 114
Study 35690026 — intervention group
Group type: EXPERIMENTAL
Intervention: ANS comparison training
Number of subjects: 87
Study 35690026 — intervention group
Group type: EXPERIMENTAL
Intervention: ANS arithmetic training
Number of subjects: 87
Study 35690026 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87
Study 33871949 — intervention group
Group type: EXPERIMENTAL
Intervention: ADSCs-assisted AFG (5 × 10^5 ADSCs/mL fat)
Number of subjects: 18
Study 33871949 — intervention group
Group type: EXPERIMENTAL
Intervention: SVF-assisted AFG (SVF:fat ratio of 1:1)
Number of subjects: 18
Study 33871949 — intervention group
Group type: COMPARATOR
Intervention: Conventional AFG
Number of subjects: 18
Study 32884253 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium
Number of subjects: 0
Study 32884253 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone
Number of subjects: 0
Study 32884253 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving ECII (D1: ≥4-unit reduction in St. George’s Respiratory Questionnaire; D2: ≥2-point reduction in COPD assessment test)
Number of subjects: 0
Study 33243533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium replacement (along with acetaminophen and ondansetron)
Number of subjects: 0
Study 33243533 — intervention group
Group type: COMPARATOR
Intervention: Placebo (acetaminophen and ondansetron)
Number of subjects: 0